The estimated Net Worth of Brice Bobzien is at least $2.23 Milion dollars as of 9 August 2024. Brice Bobzien owns over 1,372 units of iRhythm Technologies Inc stock worth over $1,827,947 and over the last 2 years Brice sold IRTC stock worth over $403,123.
Brice has made over 3 trades of the iRhythm Technologies Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Brice sold 1,372 units of IRTC stock worth $96,506 on 9 August 2024.
The largest trade Brice's ever made was selling 1,401 units of iRhythm Technologies Inc stock on 4 March 2024 worth over $155,707. On average, Brice trades about 688 units every 61 days since 2022. As of 9 August 2024 Brice still owns at least 24,428 units of iRhythm Technologies Inc stock.
You can see the complete history of Brice Bobzien stock trades at the bottom of the page.
Brice's mailing address filed with the SEC is C/O IRHYTHM TECHNOLOGIES, INC, 699 8TH ST #600, SAN FRANCISCO, CA, 94103.
Over the last 8 years, insiders at iRhythm Technologies Inc have traded over $124,847,276 worth of iRhythm Technologies Inc stock and bought 150,000 units worth $2,550,000 . The most active insiders traders include Holdings A/S Novo, Vijay K Lathi oraz Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,872,546. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth $96,506.
irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.
iRhythm Technologies Inc executives and other stock owners filed with the SEC include: